MX2019012606A - Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr. - Google Patents

Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.

Info

Publication number
MX2019012606A
MX2019012606A MX2019012606A MX2019012606A MX2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A
Authority
MX
Mexico
Prior art keywords
cd3xegfr
bispecific antibodies
seq
treatment
egfr
Prior art date
Application number
MX2019012606A
Other languages
English (en)
Inventor
STUTZ Cian
Lissilaa Rami
Blein Stanislas
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of MX2019012606A publication Critical patent/MX2019012606A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona a anticuerpos biespecíficos que se unen a CD3 y EGFR simultáneamente. Esta clase de anticuerpo ha demostrado por los inventores ser útil en el tratamiento de tumores EGFR al redirigir las células T y formar una sinapsis inmune entre las células T activadas y EGFR que expresan células tumorales, llevando a mayores niveles de matanza de células tumolares que expresan EGFR. En particular la presente invención se relaciona a anticuerpos biespecíficos de CD3xEGFR_SF4 (SEQ ID NO: 4, 5 y 9), CD3xEGFR_SD1 (SEQ ID NO: 1, 2 y 10) y CD3xEGFR_SD2 (SEQ ID NO: 11, 10 y 2).
MX2019012606A 2017-04-24 2018-04-24 Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr. MX2019012606A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17167709 2017-04-24
PCT/EP2018/060488 WO2018197502A1 (en) 2017-04-24 2018-04-24 T cell redirecting bispecific antibodies for the treatment of egfr positive cancers

Publications (1)

Publication Number Publication Date
MX2019012606A true MX2019012606A (es) 2019-12-02

Family

ID=58632245

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012606A MX2019012606A (es) 2017-04-24 2018-04-24 Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.

Country Status (11)

Country Link
US (1) US20230159661A1 (es)
EP (1) EP3615571A1 (es)
JP (1) JP2020517659A (es)
KR (1) KR20200002886A (es)
CN (1) CN110831968A (es)
AU (1) AU2018259039A1 (es)
CA (1) CA3060190A1 (es)
EA (1) EA201992143A1 (es)
MX (1) MX2019012606A (es)
SG (2) SG10201912545PA (es)
WO (1) WO2018197502A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3066133A1 (en) * 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
WO2022109611A1 (en) 2020-11-20 2022-05-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
WO2022178040A1 (en) * 2021-02-16 2022-08-25 City Of Hope Truncated domain iv egfr and uses thereof
US20230295310A1 (en) * 2022-03-20 2023-09-21 Abcellera Biologics Inc. CD3 T-Cell Engagers and Methods of Use
WO2023192514A1 (en) * 2022-03-30 2023-10-05 Pinetree Therapeutics, Inc. Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
CN114621351B (zh) * 2022-04-27 2023-01-03 华羊生物技术股份有限公司 多特异性抗体及其治疗癌症的用途
WO2024030341A1 (en) * 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof
CN117305248A (zh) * 2022-09-09 2023-12-29 复星凯特生物科技有限公司 抗EGFR和cMet双特异性嵌合抗原受体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
US10329350B2 (en) * 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
KR20150122203A (ko) * 2013-02-26 2015-10-30 로슈 글리카트 아게 T 세포 활성화 이중특이적 항원 결합 분자
MX2015014608A (es) * 2013-04-19 2016-03-03 Covagen Ag Novedosas moleculas de union biespecifica con actividad antitumoral.
CN104341504B (zh) * 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
EP3066133A1 (en) * 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
CN104774268B (zh) * 2015-01-21 2018-09-28 武汉友芝友生物制药有限公司 一种双特异性抗体egfr×cd3的构建及应用

Also Published As

Publication number Publication date
CA3060190A1 (en) 2018-11-01
SG10201912545PA (en) 2020-02-27
EP3615571A1 (en) 2020-03-04
US20230159661A1 (en) 2023-05-25
WO2018197502A1 (en) 2018-11-01
KR20200002886A (ko) 2020-01-08
AU2018259039A1 (en) 2019-11-07
JP2020517659A (ja) 2020-06-18
SG11201909498XA (en) 2019-11-28
EA201992143A1 (ru) 2020-03-13
CN110831968A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
MX2019012606A (es) Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
SA519410710B1 (ar) أجسام مضادة خاصة لأجل flt3 واستخداماتها
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
MX2020007012A (es) Anticuerpos de union a gprc5d.
CR20200303A (es) Anticuerpos anti-trem2 y métodos relacionados
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
CR20210325A (es) Anticuerpos que se unen a cd3
MY191649A (en) Antibodies to tigit
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2022001156A (es) Anticuerpos que se fijan a gprc5d.
UA120060C2 (uk) Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування
NZ760841A (en) Agonist antibodies that bind human cd137 and uses thereof
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
WO2018165062A8 (en) Anti-c5 antibodies and uses thereof
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
SA520420582B1 (ar) Cd3 أجسام مضادة خاصة لـ واستخداماتها
MX2021004454A (es) Anticuerpos anti-sinucleina.
WO2018148486A8 (en) Anti-factor d antibodies and uses thereof
PH12019502274A1 (en) Antibodies binding to steap-1
WO2019182867A8 (en) Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
MX2022000379A (es) Anticuerpos que se unen a celulas cancerosas yque dirigen radionucleidos a dichas celulas.